Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kyowa Kirin’s 6-Month Sales Up 7.5% as Global Brands Log Positive Growth
Kyowa Kirin said on August 3 that its January-June revenue surged 7.5% year on year, buoyed by growth of its global strategic products, particularly in North America, and a rise in royalty fees. In the first half of 2023, the…
To read the full story
Related Article
- Kyowa Kirin’s FY2025 Core Operating Profit Hits Record High as Costs Fall
February 10, 2026
- Kyowa Kirin Sees Flat H1 Revenue as Japan Slump Offsets Overseas Gains
August 1, 2025
- Kyowa Kirin’s Q1 Profits Down Over 50% on Higher R&D Spending
May 7, 2025
- Kyowa Kirin’s Profit Sags on R&D Spending, but Overseas Biz Fares Well
February 7, 2025
- Kyowa Kirin’s FY2023 Sales Up by 2-Digits, Operating Profit Hits Record High
February 8, 2024
- Kyowa Kirin Cuts Net Profit Forecast after Kidney Disease Drug Jettisoned
May 11, 2023
- Kyowa Kirin’s Crysvita Crosses Blockbuster Line: 2022 Earnings
February 8, 2023
- Kyowa Kirin’s Revenue Up 11.7% in January-September on Bullish Global Portfolio
November 7, 2022
- Kyowa Kirin Chief Sees Late-Stage Assets as Next Japan Biz Drivers, Room for Growth for Duvroq/Crysvita
August 8, 2022
- Kyowa Kirin Books 12.3% Growth in H1 on Global Portfolios, 9.8 Billion Yen FX Gain
August 5, 2022
BUSINESS
- China First to Approve Takeda’s Oveporexton for Narcolepsy
July 24, 2026
- FRONTEO Expects First US User of KIBIT AI Engine This Year: CEO
July 24, 2026
- Torii to Transfer Locoid MA in Japan to Cheplapharm
July 24, 2026
- Japan Vaccine Market Seen Flat in FY2026; Efluelda Delay Clouds Outlook
July 24, 2026
- Nipro Recalls Febuxostat after Finding Expired API Use at Another Plant
July 23, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…